Scleromyxedema, a therapeutic dilemma

Area of Science:

• Dermatology
• Internal Medicine

Background:

• Scleromyxedema is a rare mucopolysaccharide deposition disease.
• It typically presents with indurated, erythematous papules on the face, chest, and limbs.
• While often associated with monoclonal gammopathy, non-gammopathic forms exist.

Purpose of the Study:

• To report a challenging case of non-gammopathic scleromyxedema.
• To review treatment outcomes for scleromyxedema.
• To highlight therapeutic resistance in a long-standing case.

Main Methods:

• A comprehensive literature review of scleromyxedema treatments was performed.
• A case of a 28-year-old male with refractory scleromyxedema is presented.
• The patient received multi-drug therapy including anti-leprosy drugs, UVA1 phototherapy, and thalidomide over four years.

Main Results:

• Literature review indicates variable responses to thalidomide, stem cells, melphalan, and immunoglobulin therapies.
• The presented patient showed no improvement despite four years of multi-modal treatment.
• This case underscores the potential for treatment resistance in scleromyxedema.

Conclusions:

• Scleromyxedema management can be challenging, particularly in non-gammopathic variants.
• Therapeutic options for scleromyxedema may have limited efficacy in some patients.
• Further research into novel treatment strategies for refractory scleromyxedema is warranted.